Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: Results from the randomized CML study IV

Annals of Hematology

Volumn 93, Issue 1, 2014, Pages 71-80

  Kalmanti, Lida ^a   Saussele, Susanne ^a   Lauseker, Michael ^b   Proetel, Ulrike ^a   Müller, Martin C ^a   Hanfstein, Benjamin ^a   Schreiber, Annette ^a   Fabarius, Alice ^a   Pfirrmann, Markus ^b   Schnittger, Susanne ^c   Dengler, Jolanta ^d   Falge, Christiane ^e   Kanz, Lothar ^f   Neubauer, Andreas ^g   Stegelmann, Frank ^h   Pfreundschuh, Michael ⁱ   Waller, Cornelius F ^j   Spiekermann, Karsten ^k   Krause, Stefan W ^l   Heim, Dominik ^m   Nerl, Christoph ⁿ   Hossfeld, Dieter K ^o   Kolb, Hans Jochem ^p   Hochhaus, Andreas ^q   Hasford, Joerg ^b   Hehlmann, Rüdiger ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e KLINIKUM NÜRNBERG   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL MARBURG   (Germany)

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ Clinic Schwabing   (Germany)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^q JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

Accelerated phase; Blast crisis; Chronic myeloid leukemia; Young adults and adolescents

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; HEMOGLOBIN; IMATINIB;

ADOLESCENT; ADULT; AGE; ARTICLE; BLAST CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; FEMALE; GROUPS BY AGE; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REMISSION; SPLENOMEGALY; YOUNG ADULT;

EID: 84891850990     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1937-4     Document Type: Article

References (49)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K, (Editors) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations).Bethesda, MD:National Cancer Institute;2012http://seer.cancer.gov/ csr/1975-2009-pops09/. Accessed 10 March 2012
2. Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18):2514-2520. doi: 10.1200/jco.2011.34.7146
3. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leuk 23(3):602-604. doi: 10.1038/leu.2008.245
4. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C (1984) Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 63(4):789-799 (Pubitemid 14141296)
5. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850-858 (Pubitemid 28280552)
6. Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Shan JQ, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105-1113. doi: 10.1002/cncr.11629 (Pubitemid 37099894)
7. Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Cambrin GR, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G (2007) Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematol 92(1):101-105. doi: 10.3324/haematol.10239 (Pubitemid 46232662)
8. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591-5599. doi: 10.1182/blood-2010-12-324228
9. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematol Hematol J 97(7):1029-1035. doi: 10.3324/haematol.2011.056721
10. Stock W (2010) Adolescents and young adults with acute lymphoblastic leukemia. ASH Educ Program Book 2010(1):21-29. doi: 10.1182/asheducation-2010.1. 21
11. Advani AS (2013) Biology and treatment of acute lymphocytic leukemia in adolescents and young adults. ASCO Educ Book 2013:285-289
12. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36(3):237-249. doi: 10.1053/j.seminoncol.2009. 03.001
13. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324-3330. doi: 10.1200/jco.2007.14.2471
14. Datta RV, LaQuaglia MP, Paty PB (2000) Genetic and phenotypic correlates of colorectal cancer in young patients. New Eng J Med 342(2):137-138. doi: 10.1056/NEJM200001133420216 (Pubitemid 30036612)
15. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P, Antonescu CR (2005) Gastrointestinal stromal tumors in children and young adults - a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27(4):179-187. doi: 10.1097/01.mph.0000157790.81329.47 (Pubitemid 40604837)
16. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B (2008) The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 8(4):288-298. doi: 10.1038/nrc2349 (Pubitemid 351430865)
17. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mueller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Haenel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634-1642. doi: 10.1200/jco.2010.32.0598
18. Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 38(1):1-10. doi: 10.1002/mpo.1257 (Pubitemid 34037707)
19. Wein S, Pery S, Zer A (2010) Role of palliative care in adolescent and young adult oncology. J Clin Oncol 28(32):4819-4824. doi: 10.1200/jco.2009.22. 4543
20. Ferrari A, Thomas D, Franklin ARK, Hayes-Lattin BM, Mascarin M, van der Graaf W, Albritton KH (2010) Starting an adolescent and young adult program: some success stories and some obstacles to overcome. J Clin Oncol 28(32):4850-4857. doi: 10.1200/jco.2009.23.8097
21. Tonorezos ES, Oeffinger KC (2011) Research challenges in adolescent and young adult cancer survivor research. Cancer 117(10):2295-2300. doi: 10.1002/cncr.26058
22. Latagliata R, Breccia M, Carmosino I et al (2005) Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leukemia Research 29(3):287-291. doi: doi:dx.doi.org/10.1016/j.leukres.2004.08. 002 (Pubitemid 40127055)
23. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118(26):6760-6768. doi: 10.1182/blood-2011-08-373902
24. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28-37. doi: 2006-01-0092 [pii]10.1182/blood-2006-01-0092 (Pubitemid 43990609)
25. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leuk 13(11):1825-1832. doi: 10.1038/sj.leu.2401566 (Pubitemid 29535267)
26. Cross NC (2009) Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):355-365
27. Muller MC, Cross NCP, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leuk 23(11):1957-1963. doi: 10.1038/leu.2009.168
28. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041-6051. doi: 10.1200JCO.2009.25.0779
29. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leuk 26(10):2172-2175
30. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809-1820. doi: 10.1182/blood-2006-02-005686 (Pubitemid 44394987)
31. Pfirrmann M, Hochhaus A, Lauseker M, Sausele S, Hehlmann R, Hasford J (2011) Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 25(9):1433-1438
32. Gooley T, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competiting risks:new representations of old estimators. Stat Med 18(6):695-706 (Pubitemid 29126745)
33. Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3):1141-1154. doi: 10.1214/aos/1176350951
34. Statistical Yearbook for the Federal Republic of Germany including International tables (2011). Federal Statistical Office, Wiesbaden
35. Bleyer A OLM, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival:1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006. http://seer.cancer.gov/publications/aya/. Accessed 10 March 2012.
36. Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J, Suttorp M (2009) Correlation of BCR/ABL transcript variants with patients characteristics in childhood chronic myeloid leukemia. Eur J Haematol 82(2):112-118
37. Millot F, Suttorp M, Guilhot J, Sedlacek P, De Bont ES, Li CK, Kalwak K, Lausen B, Srdjana C, Dresse M-F, Biondi A, Baruchel A (2012) The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): objectives and preliminary results. ASH Annu Meeting Abstracts 120(21):3741
38. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, Plantaz D, Bertrand Y, Bordigoni P, Guilhot F (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatr 116(1):140-143. doi: 10.1542/peds.2004-2473
39. Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Goehring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Haenel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A, Sakk GCMLSG (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leuk 26(9):2096-2102. doi: 10.1038/leu.2012.85
40. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232-238. doi: 10.1200/jco.2011.38.6565
41. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. doi: 10.1182/blood-2013-05-501569
42. Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342(2):69-77. doi: 10.1056/nejm200001133420201 (Pubitemid 30036597)
43. Vriens M, Moses W, Weng J et al (2011) Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 117(2):259-267
44. Harrison CJ (2009) Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 144(2):147-156. doi: 10.1111/j.1365-2141. 2008.07417.x
45. Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon F-X (2007) Imatinib and Nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biology & Therapy 6(6):912-919 (Pubitemid 351574982)
46. Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R (2013) Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood 121(10):1824-1838. doi: 10.1182/blood-2012-02-412890
47. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevarn B, Olofsson T, Olsson-Stromberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H (2013) Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leuk 27(7):1520-1526. doi: 10.1038/leu.2013.19
48. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408-2417. doi: 10.1056/NEJMoa062867 (Pubitemid 44903745)
49. Aben KKVGC, Van Gils NA, Van der Graaf WT, Zielhuis GA (2012) Cancer in adolescents and young adults (15-29 years): a population-based study in the Netherlands 1989-2009. Acta Oncologica 51(7):922-933. doi: 10.3109/0284186X. 2012.705891